Prognosis of follicular lymphomas

Clinical Lymphoma

Volumn 6, Issue 1, 2005, Pages 21-25

  Solal Celigny, Philippe ^a  

^a CENTRE JEAN BERNARD   (France)

Author keywords

Follicular lymphoma international prognostic index; Non Hodgkin's lymphoma; t(14; 18) translocation

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; HEMOGLOBIN; LACTATE DEHYDROGENASE; PROTEIN BCL 2; PROTEIN P53; RITUXIMAB; BETA 2 MICROGLOBULIN; CA 125 ANTIGEN; HUMAN SERUM ALBUMIN;

ADULT; AGE; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 17P; CHROMOSOME 3Q; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 18; CHROMOSOME TRANSLOCATION 3; FEMALE; FOLLICULAR LYMPHOMA; GENE EXPRESSION PROFILING; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MEDICAL DECISION MAKING; PROGNOSIS; PROTEOMICS; RETROSPECTIVE STUDY; REVIEW; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; TUMOR LOCALIZATION; WORLD HEALTH ORGANIZATION; CYTOGENETICS; CYTOPENIA; ERYTHROCYTE SEDIMENTATION RATE; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPH NODE METASTASIS; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; SPLENOMEGALY; TUMOR VOLUME;

EID: 22944455903     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2005.n.022     Document Type: Review

References (32)

1. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993; 20:75-88.
2. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplasic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:3835-3849.
3. Bartlett NL, Rizeq M, Dorfman R, et al. Follicular large-cell lymphoma: intermediate or low-grade? J Clin Oncol 1994; 12:1349-1357.
4. Mann RB, Berard CW. Criteria for the subclassification of follicular lymphomas: a proposed alternative method. Hematol Oncol 1983; 1:187-192.
5. Hans CP, Weinsenburger DD, Vose JM, et al. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 2003; 101:2363-2367.
6. Martin AR, Weisenburger DD, Chan WC, et al. Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood 1995; 85:3671-3678.
7. Barrans S, Randerson J, Evans P et al. Heterogeneity in cell proliferation and expression of p53 and bcl-2 during the indolent phase of germinal centre cell lymphoma: an explanation for clinical variability. Br J Haematol 1995; 90:830-836.
8. Tiesinga JJ, Wu CD, Inghirami G. CD5+ follicle center lymphoma. Immunophenotyping detects a unique subset of "floral" follicular lymphoma. Am J Clin Pathol 2000; 114:912-921.
9. Lopez-Guillermo A, Cabanillas F, McDonnell TI, et al. Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma. Blood 1999; 93:3081-3087.
10. Ott G, Katzenberger T, Lohr A, et al. Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood 2002; 99:3806-3812.
11. Liu NS, Medeiros LJ, Cabanillas F, et al. Prognostic relevance of t(14;18) status in follicular lymphoma (FL). Proc Am Soc Clin Oncol 2003; 22:577 (Abstract# 2319).
12. Tilly H, Rossi A, Stamatoullas A, et al. Prognostic value of chromosomal abnormalities in follicular lymphoma. Blood 1994; 84:1043-1049.
13. Sander CA, Yano T, Clark HM, et al. p53 mutation is associated with progression in follicular lymphomas. Blood 1993; 82:1994-2004.
14. Bosga-Bouwer AG, van Imhoff GW, Boonstra R, et al. Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other trauslocations: t(14;18) and 3q27 are mutually exclusive. Blood 2003; 101:1149-1154.
15. Romaguera JE, McLaughlin P, North L, et al. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model. J Clin Oncol 1991; 9:762-769.
16. Maartense E, le Cessie S, Kluin-Nelemans HC, et al. Age-related differences among patients with follicular lymphoma and the importance of prognostic scoring systems: analysis from a population-based non-Hodgkin's lymphoma registry. Ann Oncol 2002; 13:1275-1284.
17. Gallagher CJ, Gregory WM, Jones AE, et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 1986; 4:1470-1480.
18. Bastion Y, Berger F, Bryon PA, et al. Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years. Ann Oncol 1991; 2(suppl 2):123-129.
19. Litam P, Swan F, Cabanillas F, et al. Prognostic value of serum beta-2 microglobulin in low-grade lymphomas. Ann Intern Med 1991; 114:855-860.
20. Benbouker L, Valat C, Linassier C, et al. A new serologic index for low-grade non-Hodgkin's lymphoma based on initial CA125 and LDH serum levels. Ann Oncol 2000; 11:1485-1491.
21. Decaudin D, Lepage E, Brousse N, et al. Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients - a study of the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1999; 17:2499-2505.
22. Federico M, Vitolo U, Zinzani PL, et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood 2000; 95:783-789.
23. Leonard RC, Hayward RL, Prescott RJ, et al. The identification of discrete prognostic groups in low-grade non-Hodgkin's lymphoma. The Scotland and Newcastle Lymphoma Group Therapy Working Party. Ann Oncol 1991; 2:655-662.
24. Solal-Celigny P, Lepage E, Brousse N, et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity of the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol 1998; 16:2332-2338.
25. Horning SJ, Negrin RS, Hoppe RT et al. High dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood 2001; 97: 404-409.
26. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329:987-994.
27. Hermans J, Krol AD, van Groningen K, et al. International prognostic index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood 1995; 86:1460-1463.
28. Lopez-Guillermo A, Montserrat E, Bosch F, et al. Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 1994; 12:1343-1348.
29. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89:3909-3918.
30. Aviles A. The International Index is not useful in the classification of low-grade lymphoma. J Clin Oncol 1994; 12:2766-2770.
31. Foussard C, Desablens B, Sensebe L, et al. Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage III-IV patients. The GOELAMS Group, France. Ann Oncol 1997; 8(suppl 1):49-52.
32. Solal-Céligny P, Roy P, Colombat P, et al. Follicular Lymphoma International Prognostic Index. Blood 2004; 104:1258-1265.